Join a Study
Scientists at the medical school are conducting hundreds of clinical trials daily. Browse our list of actively recruiting clinical trials below to learn more and find out how you may be able to participate.
For more information about the research or participation, please call our research office at 312-503-0755 or email us at pdclinicaltrials@northwestern.edu. Learn more about all the medical school's trials via the Feinberg Research Clinical Trials section, including Volunteer FAQ.
| Trials |
|---|
This is a registry aimed to collect biologic and clinical information, such as blood and tissue samples, and family and medical histories from patients diagnosed with a movement disorder. The purpose of studying materials from the registry is to identify factors that either cause these neurologic co… This is a registry aimed to collect biologic and clinical information, such as blood and tissue samples, and family and medical histories from patients diagnosed with a movement disorder. The purpose of studying materials from the registry is to identify factors that either cause these neurologic conditions or increase one’s risk for developing them. Samples collected for this biorepository include a blood sample (or a saliva sample) and a skin biopsy. Participants may choose to donate one or both samples. |
The purpose of this research study is to collect clinical information about patients and their health. We will also collect biological samples, such as blood and DNA (the genetic material in your blood). Researchers will use this information and samples to learn more about HD and to try to find new … The purpose of this research study is to collect clinical information about patients and their health. We will also collect biological samples, such as blood and DNA (the genetic material in your blood). Researchers will use this information and samples to learn more about HD and to try to find new treatments for the disease. People from many countries contribute to Enroll-HD. Individuals 18 yrs or older affected by Huntington's Disease (HD) or from a HD family or are a "community control" (a person who does not carry the HD genetic mutation that causes Huntington's disease and is not part of an HD family, but would like to participate in the study). Research visits are conducted yearly and will consists of a collection of medical and family history and biological samples.
STU00203021 |
The purpose of this study is to collect natural history data among ataxia patients in a cohort of SCA 1, 2, 3, 6 patients using clinic-based neurological rating scales and performance measures. Another study goal is to identify new measures of ataxia, cognition, and neurobehavior in comparison to tr… The purpose of this study is to collect natural history data among ataxia patients in a cohort of SCA 1, 2, 3, 6 patients using clinic-based neurological rating scales and performance measures. Another study goal is to identify new measures of ataxia, cognition, and neurobehavior in comparison to traditional clinician rating methods. The gene analysis is expected to establish a relationship, if any, between age at onset of disease and disease progression rates. • Age 18 and older • Presence of symptoms and signs of ataxia • Molecular diagnosis of SCA 1, 2, 3, 6 either in the participant or an affected family member • Willingness to participate in the study and ability to give informed consent.
NCT01060371 STU00204294 |
The purpose of study is to determine whether BIIB094 may improve PD symptoms in subjects with or without changes in the LRRK2 gene. The study medication will be given as an injection into your back near the spinal cord. This iscalled an “intrathecal” injection. 2. Diagnosis of PD w/in 7yrs without motor fluctuationsor dyskinesia. 3. Not on any medication for PD or on stable therapy for 8weeks prior to screening.
NCT03976349 STU00210196 |
This study is a Phase 3 multi-site, randomized, evaluator-masked, study of endurance treadmill exercise on changes in the MDS-UPDRS Part III score at 12 months. Subjects will be randomly assigned to 2 endurance exercise groups: 1) moderate intensity exercise: 60-65% HRmax or 2) high intensity exe… This study is a Phase 3 multi-site, randomized, evaluator-masked, study of endurance treadmill exercise on changes in the MDS-UPDRS Part III score at 12 months. Subjects will be randomly assigned to 2 endurance exercise groups: 1) moderate intensity exercise: 60-65% HRmax or 2) high intensity exercise: 80-85% HRmax. The endurance exercise will be 4 days per week for approximately 30 minutes per session for 18 months. -Diagnosis of Parkinson's disease for less than 3 years -Cannot be treated with any PD medication NCT04284436 STU00211903 |
PR001A is an investigational gene therapy product that is being developed for the treatment of PD in patients with GBA1 mutations. The purpose of this study is to find out what effects PR001A has on Parkinson’s disease patients. Participants will be assigned to receive one dose of PR001A by inject… PR001A is an investigational gene therapy product that is being developed for the treatment of PD in patients with GBA1 mutations. The purpose of this study is to find out what effects PR001A has on Parkinson’s disease patients. Participants will be assigned to receive one dose of PR001A by injection into the cisterna magna (a large space at the base of the brain). 1. 40-75 years of age. 2. Diagnosis of PD with H&Y 3-4. 3. On stable PD therapy for 8 weeks prior to baseline. 4. At least 1 GBA gene mutation.
NCT04127578 STU00209947 |
The purpose of this study is to obtaininformation from people with and without Parkinson disease (PD) so thatresearchers may better understand how Parkinson disease progresses, in order toinform better treatments. Participants will have a neurological examination, a brain scan, provide blood samples… The purpose of this study is to obtaininformation from people with and without Parkinson disease (PD) so thatresearchers may better understand how Parkinson disease progresses, in order toinform better treatments. Participants will have a neurological examination, a brain scan, provide blood samples and complete some questionnaires. |
The purpose of this study is to evaluate the safety and effectiveness of the study drug, pridopidine,on everyday functioning and daily activities, as well as movement and behaviorin participants with early stage Huntington Disease (HD) 1. >25yrs of age. 2. Diagnosis of HD with CAG repeat > 36
NCT04556656 STU00213780 |
This study is for people with early-stage Parkinson's disease. The objective of this study is to find out whether UCB0599, an investigational medication, can slow down the progression of PD. This study also tests whether UCB0599 is safe and tolerable. This study is placebo-controlled and will … This study is for people with early-stage Parkinson's disease. The objective of this study is to find out whether UCB0599, an investigational medication, can slow down the progression of PD. This study also tests whether UCB0599 is safe and tolerable. This study is placebo-controlled and will last about 21 months. If you join the study, you will have regular scheduled appointments with the study staff and will have medical procedures and tests during these visits, like imaging studies, body function tests, and questionnaires. You might be a candidate for this study if:
There are additional eligibility criteria that will be discussed with you.
NCT04658186 STU00214389 |
The purpose of this research study is to assess if an investigational product (study drug), called UX701, is an effective and safe treatment for adults aged 18 years or older with Wilson disease. 1.Individuals ≥ 18 years of age at the time of informed consent. 2. Confirmed diagnosis of Wilson disease. 3. Stable Wilson Disease with no medication or dose changes for at least 6 months at Screening. 4. Ongoing restriction of high copper containing foods for at least 6 months at Screening and continued through study participation. NCT04531189 STU00214772 |
This study is for people who have Parkinson's disease (PD), multiple system atrophy (MSA), or progressive supranuclear palsy (PSP). The objective of this study is to find out whether an advanced imaging study can distinguish people with PD, MSA, or PSP from one another. The imaging study uses a b… This study is for people who have Parkinson's disease (PD), multiple system atrophy (MSA), or progressive supranuclear palsy (PSP). The objective of this study is to find out whether an advanced imaging study can distinguish people with PD, MSA, or PSP from one another. The imaging study uses a brain MRI (without dye or contrast) along with a web-based automated software tool that analyzes the MRI data automatically. The study requires two visits, one at the start and one 12-18 months later. The MRI is only performed at the first visit. At each visit, there are assessments of movement and thinking, along with several questionnaires.
STU00214779 |
This is a multicenter, randomized, double-blind, placebo-controlled study that will evaluate the efficacy and safety of intravenous (IV) prasinezumab versus placebo in participants with Early Parkinson's Disease (PD) who are on stable symptomatic PD medication. • Diagnosis of PD for at least 6 months to maximum 3 years at screening and between 50-85 years of age • On symptomatic PD medication for at least 6 months, with a stable dose for 3 months prior to baseline • No dyskinesisa or motor fluctuations (i.e. MDS-UPDRS Part IV = 0) NCT04777331 STU00214429 |
The purpose of this study is to determine whether smartphone app-based digital speech assessments can provide speech data that is of sufficient quality and compliance to support analysis and are usable and relevant to PD and prodromal PD patients with varying ranges of speech symptom severi… The purpose of this study is to determine whether smartphone app-based digital speech assessments can provide speech data that is of sufficient quality and compliance to support analysis and are usable and relevant to PD and prodromal PD patients with varying ranges of speech symptom severity. |
The primary objective of the study is to assess the impact of the frequency of assessments on the variability over time, reliability, and compliance for the PD diary in patients with PD in whom medications do not provide adequate control of symptoms. 1.≥39 to ≤70 years of age at signing of informed consent 2. Diagnosis of clinically established PD 3. Marked levodopa responsiveness at screening per investigator’s judgment 4. A minimum of 3 years and a maximum of 18 years from time of PD diagnosis to the date of screening 5. Receiving optimized and stable PD medical therapy for ≥1 month prior to screening or demonstrated intolerance to PD medications per investigator’s judgment in agreement with the medical monitor 6. ≥3 hours of average daily OFF-time assessed within 3 months of screening by PD diary or per investigator’s judgment
STU00217962 |
The purpose of this study is to evaluate the safety of tominersen compared with placebo. The study drug will be administered via intrathecal injection. NCT05686551 STU00218483 |
The primary objective of this study is to determine whether adjunctive use of Ceregate therapy reduces freezing of gait (FOG) in participants diagnosed with Parkinson's disease. Participants diagnosed with Parkinson’s Disease (PD) and previously implanted with a subthalamic nucleus deep brain stimulation (STN-DBS) System. NCT05292794 STU00218900 |
The purpose of this study is to evaluate the efficacy of suvecaltamide administered once daily for 17 weeks to improve functional and performance-based impairment due to tremor. NCT05642442 STU00218068 |
The purpose of this study is to evaluate the safety and initial efficacy of ECAP-controlled closed-loop spinal cord stimulation (SCS) to treat patients with Parkinson’s Disease symptoms. Subject must have moderate/severe freezing of gait and/or tremor considered as a significant source of impairment in the management of their Parkinson's disease. NCT02924129 STU00220312 |